



## Disrupting convention in women's health through continuous innovation.

Femasys is a leading biomedical innovator committed to providing women with revolutionary products as they seek solutions throughout their reproductive journey. Technological advancements in female reproductive health are long overdue, driving our focus to develop in-office, accessible, and innovative options.



## Investment Highlights

### MISSION

- Develop disruptive broad portfolio of market-first solutions for women's health that improve patient care and healthcare economics.
- Address multi-billion dollar global market opportunities in infertility treatment and diagnosis and permanent birth control with differentiated, clinically validated, and improved approaches.

### DIFFERENTIATOR

- Minimal competition with well defined reimbursement strategies.
- Global regulatory approvals achieved in U.S., Europe, United Kingdom, Canada, Japan, Israel, Australia & New Zealand.
- Commercial-readiness with in-house CMC and device manufacturing.
- Supply chain control; no reliance on third-party manufacturing.

### FOUNDATION


- Woman-founded and led; experienced leadership team with concentrated development expertise.
- Intellectual property portfolio with over 200 patents issued globally.

### OPPORTUNITY

- Near term revenue inflection with first time OB/GYN fertility portfolio execution.
- Compelling economics for patients, physicians, and practices supporting paradigm shift.



## Commercializing Multi-Asset Women's Health Portfolio



# Fertility in Crisis – Massive Unmet Need

FEMASYS

## Fertility Fasttrack™

- First-line infertility treatment for targeted sperm delivery in the fallopian tube where conception occurs.
- Positive clinical trial results with 26.3% of patients becoming pregnant, establishing more than double pregnancy rate when compared to historic intrauterine insemination (IUI) for similar patient population of low male sperm count<sup>1</sup>.
- Indicated for use for anyone desiring insemination (i.e. infertile woman/ couple, same sex couples, single woman) for a safe, effective, cost-affordable approach.
- Seamless integration into existing OB/GYN workflows, representing the first product portfolio offering to enable new procedures with compelling economics.
- Patients can remain under the care of their trusted OB/GYN and receive accessible care addressing significant unmet patient urgency.

~10M

U.S. women with **infertility**<sup>2</sup>  
(~50% male factor contribution<sup>3</sup>)

~5M

Take first step and undergo **infertility testing**<sup>4</sup>

~100K

Receive **IVF** transfer cycle<sup>5</sup>



**2025: U.S. fertility rate dropped to another record low<sup>6</sup>**

1. Liu, J. H., et al. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.
2. [https://www.cdc.gov/nchs/nsgf/key\\_statistics/i-keystat.htm](https://www.cdc.gov/nchs/nsgf/key_statistics/i-keystat.htm)
3. Kumar N, et al. (2015). doi: 10.4103/0974-1208.170370.
4. Nugent CN, Chandis A. Use of fertility services in women ages 20-49 in the United States: 2022-2023. NCHS Data Brief, 2025 Dec;(542):1-10. DOI: <https://dx.doi.org/10.15620/cdc/174628>
5. Centers for Disease Control and Prevention. 2022 Assisted Reproductive Technology (ART) Fertility Clinic and National Summary Report. US Dept of Health and Human Services; 2024.
6. Hamilton BE, Osterman MJ, Gregory ECW. Births: Provisional data for 2025. Vital Statistics Rapid Release, 2026 Apr;(43):1-7. DOI: <https://dx.doi.org/10.15620/cdc/252434>.

### DIAGNOSE

### PREPARE

### TREAT

**FemVue®**  
Diagnosis - HER

**SpermVue™**  
Diagnosis - HIM


**FemSperm®**  
Sperm Handling

**FemaSeed®**  
Intratubal Insemination

✓ OB/GYN qualifies patients in-office

✓ Leverages existing workflows (no lab required)

✓ First-line fertility treatment in OB/GYN office



# Permanent Contraception – Critical Gap

**femBloc®**

Currently enrolling in **FINALE** pivotal trial for U.S. approval

## Non-Surgical Permanent Birth Control

- Potential to be the safest and most natural approach at substantially less cost than the long-standing surgical alternative.  
Note: no implant, no hormones, no incisions, and no anesthesia.
- Positive clinical trial results with 0% pregnancy rate, establishing compelling evidence of efficacy. No new safety concerns through 5-years and no serious adverse events<sup>1</sup>.
- FDA approved IDE to conduct Stage III pivotal clinical trial (the "FINALE" trial, NCT05977751); trial enrollment underway.
- Over 100 years of stagnant innovation could lead to \$20 billion market expansion opportunity for FemBloc in the U.S. alone.

~13M

U.S. women **no longer** intend to have children<sup>7,8</sup>

~12M

Remain on form of **temporary birth control**<sup>9</sup>

~1.2M

Elect **surgical sterilization** every year<sup>8,10</sup>



**Today: Only surgery remains an option**

7. Jones et al. Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995. National health statistics reports, no 60. Hyattsville, MD: National Center for Health Statistics; 2012.

8. Daniels et al. Current contraceptive status among women aged 15-49. United States, 2017-2019. NCHS Data Brief, no 388. Hyattsville, MD: National Center for Health Statistics; 2020.

9. National health statistics reports, no 60. Hyattsville, MD: National Center for Health Statistics; 2012.

10. Martinez GM. Receipt of family planning services in the United States: 2022-2023. NCHS Data Brief, no 520. Hyattsville, MD: National Center for Health Statistics; 2024. DOI: <https://dx.doi.org/10.15620/cdc/169629>

This Corporate Overview contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, results of clinical trials and other future conditions. Words such as, but not limited to, "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes, identify forward-looking statements.

## Contact

femasys.com  
770-500-3910  
Customer service:  
877-336-2562



Femasys Inc.  
3950 Johns Creek Court,  
Suite 100  
Suwanee, Georgia 30024



Main: 404-521-4219